Good afternoon and welcome to Kestra Medical Technologies first quarter fiscal 2027 earnings conference call. This conference call is being recorded for replay purposes. We will be facilitating a question and answer session following prepared remarks from management. At this time, all participants are in a listen-only mode. I would now like to turn the call over to Neil Bhalodkar. of Vice President of Investor Relations for introductory comments.

Thank you, Lateef. Good afternoon. Thank you for joining Kestra's first quarter fiscal 2027 earnings call. With me today are Brian Webster, President and Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer. This call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements. These statements are based on KESTRA's current expectations, forecasts, and assumptions, which are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Actual outcomes and results could differ materially from any results, performance, or achievements expressed or implied by the forward-looking statements due to various factors. Please review Kestra's most recent filings with the SEC, particularly the risk factors described in our Form 10-K for additional information. Any forward-looking statements provided during this call, including projections of future performance, are based on management's expectations as of today. Kestra undertakes no obligation to update these statements except as required by applicable law. During today's call, we will also discuss non-GAAP financial measures. These non-GAAP financial measures are in addition to and are not a substitute for or superior to measures of financial performance prepared in accordance with GAAP. Please refer to our earnings release for a reconciliation of these measures to their most directly comparable GAAP financial measures. With that, I will turn the call over to Brian.

Thanks, Neil. Good afternoon and thank you for joining us on today's conference call. We're excited to discuss the strong financial performance we had in the first quarter and the continued progress we are making on our key operational objectives. I'd like to begin, though, with a reminder of the purpose behind our work, that is providing innovative, intuitive medical technologies that protect and support at-risk patients. That mission guides both the technology we create and the experience we deliver Helping patients remain engaged, connected, and protected throughout their care. One patient's experience this quarter demonstrates how those forms of protection work together. The patient was prescribed the AssureWCD for protection during the high-risk period between removal of his implanted defibrillator and scheduled lead extraction. Shortly after fitting, The Assure System recorded more than 120 diverted therapies in one night, prompting immediate outreach from our Heart Alert Services team. The team learned the patient was driving alone through rural Utah with his two dogs. He initially resisted seeking care. Heart Alert Services remained in close contact until he agreed to go to the nearest emergency department. The team sent his clinical reports ahead to the support team at the emergency department. Upon arrival, clinicians determined he needed to be airlifted to a Las Vegas hospital for specialized electrophysiology care. After eight days in the hospital, he underwent a successful lead extraction and received a replacement device. This case demonstrates the differentiated value of our integrated care model. Assure provided continuous protection and clinical insight, while heart alert services turned that insight into action, moving a patient from unseen risk to urgent specialized care, in this case, across state lines. This is the cardiac recovery system platform in action, therapeutic protection, clinical insight and responsive support working together when it matters most. I would now like to turn to our recent financial performance. In the first quarter, we continued to reach more patients at risk of dangerous cardiac arrhythmias while delivering another quarter of strong financial performance. Revenue advanced sequentially off a strong fourth quarter and grew 60% year over year to $31 million. Gross margin of 56.5% increased over 10 points year over year and 175 basis points sequentially. This was the 11th quarter in a row of sequential gross margin expansion, demonstrating the attractive unit economics and volume leverage of our business model. Based on the progress to date, we are increasingly confident that Kestra can achieve mid-70s gross margin percentage in the next few years. This represents a meaningful increase from our previously communicated target of 70%. Importantly, though, Kestra is not simply a gross margin story. With strong revenue growth and gross margin expansion, we are enhancing the operating leverage in our business. This leverage supports investments we are making in key growth drivers that we believe will yield significant earnings power and long-term value for Kestra and its stakeholders in years ahead. We have been deliberately building towards this point. For example, we have invested in building the foundational technology stack needed to scale the business, including cloud platforms, Enterprise Data Capabilities, Workflow Automation, and System Integration Layers. Those investments are now enabling the next phase of value creation through AI and automation. Our AI roadmap is highly disciplined and firmly grounded in measurable business outcomes. Every initiative is linked to a specific operating KPI. and evaluated based on its ability to improve growth, efficiency, or enhance scalability. We are initially prioritizing three areas where we believe AI and automation can create significant value. First, patient support and adherence, where AI-powered patient support agents and automated outreach can help maintain patient engagement and Ware Compliance while increasing the productivity of the KESPER team supporting a rapidly growing patient base. Second, revenue access and collections. We're automating intake, prior authorization and reimbursement workflows can improve our fittings to claim conversion and collections while materially reducing administrative effort. And third, Commercial Demand Acceleration, where AI assists our sales representatives with call preparation, follow-up, account prioritization, and clinical documentation. The objective here is straightforward. Increase rep productivity as measured by patient fittings per rep without requiring a proportional increase in head count. Together these initiatives demonstrate the leverage in the technology foundation we have built and how AI and automation can improve key operating metrics while bending the operating expense curve as transaction volumes continue to grow. Turning to our commercial organization, our territory managers are continuing to win share in competitive accounts while simultaneously expanding the WCD market as prescribers increasingly recognize the benefits of protecting more patients than they have historically. Our newest reps are ramping faster than prior cohorts while our legacy reps continue to generate strong growth and same store sales. In some of our largest markets, we have been deliberate and strategic about splitting high volume platinum territories to go deeper and reach more prescribers in existing accounts. We are finding that when we split a territory and add a clinical account specialist, more feet on the ground closer to the customer compounds growth. It's how we ultimately turn a foothold into a fully penetrated account and put both territories on a path to becoming high-volume, platinum territories. This is a powerful model for growth and operating leverage. Higher territory manager productivity is a meaningful driver of operating leverage and also positions us to more effectively capitalize on a significant growth opportunity ahead of us, given how under-penetrated the WCV category remains. As we have previously noted, Despite the overwhelming evidence that external fibrillation shock is effective at terminating dangerous cardiac rhythms, WCD therapy remains underutilized. In 2025, six out of seven patients that were indicated for a WCD were not protected by one. This statistic speaks to the enormous potential in front of us. The innovation and clinical evidence we have brought to the category is beginning to change this. Based on our financials and those of the incumbent, the WCD market grew approximately 14% on a dollar basis in the 12 months into July of 2026. We believe we are still in the early innings of market expansion and we see this category growing into a multi-billion dollar market in the years ahead. Turning to market access, we continue to bring more payers in-network while also making progress on improving our RCM capabilities. At the time of our IPO 18 months ago, approximately 70% of our fittings were for patients with in-network benefits. This figure is now in the low 80s, and we expect this to increment higher in our FY27 as we sign new contracts in target markets. Higher in-network mix meaningfully increases our team's efficiency and positively impacts all RCM metrics, including revenue per patient. About six months ago, we announced that Kestra had been added to the federal supply schedule for the U.S. Department of Veterans Affairs. As a reminder, the VA is the largest integrated healthcare network in the U.S. and covers 9 million members. nearly 50% of whom are over the age of 65. Over the last six months, we have seen a steady increase in volumes at the VA and still have a significant multi-year opportunity to grow our share within these facilities. It is important to note that there are over 3,000 payers in the U.S., so there is still a long tail of regional and local payers we are working to bring under contract. Of note, this month a significant national payer has expanded their coverage to non-ischemic patients undergoing guidelines directed medical therapy. This is the first time this large payer has covered both the ischemic and non-ischemic patients. This is significant since over 60% of the typical WCD populations are non-ischemic. We believe this is a strong signal that the recent clinical evidence is having an impact on payer policies for WCBs. Innovation also continues to be a central area of focus and investment for Kestra. We are progressing as planned with our BioV technologies partnership to integrate non-invasive blood pressure monitoring into the Assure platform. In addition, our team is completing an exciting late-stage R&D project intended to further extend our clinical advantage with the performance of the Assure system and also bring new first-in-category capabilities to the market. We expect to discuss those further in the next quarter. Over time, we believe innovation will help us accelerate market growth and win additional market share by further differentiating our product from the incumbent. And more importantly, by providing additional clinical value and diagnostic insights to physicians, we believe it will result in them prescribing WCDs to more of their patients that heretofore have gone unprotected. In conclusion, the fundamentals of Kester's story have never been stronger. Our product differentiation is clear and compelling. The WCD market is expanding rapidly with tremendous room for further penetration. Casper continues to deliver top-tier MedTech revenue growth. Gross margin has expanded consistently, and meaningful opportunity remains. We have a strong balance sheet, and our execution continues to be crisp and the foundation we have built positions Kester for strong and durable growth for years to come. I'd like to thank our incredible team in the field and also here at the home office in Kirkland for their passion and commitment to the Kester mission. I will now turn it over to Vaseem who will discuss first quarter financial results in more detail and provide our updated fiscal year 2027 revenue guidance.

Vaseem? Thank you, Brian, and good afternoon, everyone. We had a strong financial performance across the board in the first quarter. Total revenue was $31 million, an increase of 60% compared to the prior year period. Revenue growth was driven by continued WCD market expansion, competitive share gains, a higher mix of in-network patients, and ongoing improvements in our revenue cycle management capabilities. We continue to see improvements in all three key drivers of our revenue model, our prescription bill rate, our bill rate, and our collections performance. As we continue to bring more payers in network, we expect to see benefits in revenue growth, gross margin, and our profitability profile. As Brian noted in his prepared remarks, we are investing in RevCycle AI tools and other automation projects that we believe will drive significant operating leverage as we scale the business. Turning to gross margin, our gross margin increased to 56.5% in the first quarter versus 45.7% in the prior year period. This continued expansion in our gross margin was driven by attractive unit economics inherent in gastronomic business model, an increase in revenue per fit from more in-network patients, and a decline in cost per fit driven by the volume leverage and execution of cost improvement projects. In the quarters ahead, we expect to see steady and consistent increases in our gross margin as our rental model benefits from higher fixed. We are confident in our ability to achieve a mid-70% margin in the next few years, which is higher than our prior outlook of 70% gross margins. Gap operating expenses were $55.2 billion in the first quarter, compared to $37.7 million in the prior year period. Included in GAAP operating expense are $1.4 million of non-recurring items related to a BioLeak milestone payment and one-time professional fees related to a key R&D project that Brian noted we will be discussing in detail in the next quarter. Excluding non-recurring costs and stock-based compensation, operating expenses were $44.2 million in the first quarter, compared to $30.3 million in the prior year period. The increase was primarily attributable to growth in expenses related to the company's commercial expansion and accelerated investment in our late-stage R&D programs. Gas net loss was $44.1 million in the first quarter, compared to a gap net loss of $25.8 million in the prior year period. Adjusted EBITDA loss was $24 million in the first quarter compared to an adjusted EBITDA loss of $19.4 million in the prior year period. Our cash used from operating activities in the first quarter was $32.3 million. As expected, our Q1 cash flow was higher on a sequential basis driven by payout for company-wide bonus and Timing of Payments to Suppliers. We expect our burn to decline sequentially throughout fiscal year 2027 as it did in fiscal year 2026. In July, we announced a new $200 million term loan facility. This non-diluted financing was a great outcome from KESRA. It fortifies our balance sheet, reduces our cost of capital, and provides a significant financial flexibility to invest in our commercial strategies and expand our fleet to drive durable, best-in-class growth for years to come. Cash, cash uploads and investments total $245 million as of July 31. Including unused committed availability under our term loan agreement, Castra has a liquidity of approximately $320 million. In summary, we continue to deliver top-tier MedTech revenue growth while significantly expanding our gross margins and Fortifying Our Balance Sheet. Our investments in the field team, RCM capabilities and R&D initiatives position Kestra to capitalize on the large and growing WCD market opportunity and drive durable revenue growth for years to come. And while we are continuing to invest in our growth strategy in fiscal year 2027, you will see Kestra drive increasing levels of operating leverage each year going forward. For these reasons, we have high visibility and confidence in our path to profitability over the next few years. I will now provide updated fiscal year 2027 revenue guidance. We expect revenue of $141 million, representing growth of 48% compared to fiscal year 2026. This compares to prior fiscal year 2027 revenue guidance of $137 million. We expect FedEx growth to be driven by deeper penetration within existing accounts and the activation of new accounts as we invest in the regional coverage. We expect growth in revenue per fit to be driven by a higher mix of in-depth rotations and continued investments in RF cycle management capabilities. With that, Operator, we have concluded our prepared remarks and are ready to proceed to the Q&A portion of the call. Operator?

Thank you. As a reminder, to ask a question, you will need to press star 11 on your telephone. To remove yourself from the queue, you may press star 11 again. Please limit yourself to one question and one follow-up to allow everyone the opportunity to participate. Please stand by while we compile the Q&A roster. Our first question comes from the line of Larry Beagleson of Wells Fargo. Your line is open, Larry.

All right. Good afternoon. Thanks for taking the question. Congrats on the nice start to the year here. Brian or Vaseem, I wanted to ask about the guidance and the cadence. So you beat by about $2 million, raised by about $4 million. So my question is, what gave you the confidence to raise by more than the beat this quarter? and how should we think about the cadence the rest of the year? I think you said on the last call you expect an acceleration in the second half due to some of the reps you hired last year, and I had one follow-up.

Yeah, hey, Nathan, thanks for the question. Our fiscal year 2027 guidance of $141 million implies a 48% growth, which is among the highest in small-cap med tech. Our revenue growth has historically been driven by prescription wedding growth, in-network mix, and RCM improvements, and the growth of our field team. These KPIs are all tracking in the right direction and give us a lot of confidence in increasing our guidance to 48% growth in fiscal year 2027. Higher prescriptions will be driven by winning new accounts, going deeper in existing accounts, and market expansion. We expect revenue per fit to benefit from higher in-network mix as we continue to make progress on their coverage. And as we said last year, same time, We do expect those reps to ramp up here in the second half of the year. So we expect the second half to be faster than the first half.

That's helpful. And just for my follow-up, Brian, on the pipeline, I guess update on BioBeat and any milestones. I guess I've got to try to ask about this new pipeline product. Just any color on kind of where you're focused. Is it the patient experience, the algorithm? New features and how far away from market is this? Anything you could share? Thanks.

Yeah, I appreciate the question. We do expect to be able to talk about it in more depth over the next quarter. We're not quite ready to do that yet, but I will say that what we expect to do with the new technology is leverage the platform that we've developed and extend that platform, give it additional capability, as I mentioned in my comments, capability that doesn't exist in WCD today. And so we're excited about that. That's part of why we're investing into that and excited to discuss that with you all over the next few months. All right, thank you.

Thank you. Our next question comes from the line of Matthew O'Brien of Piper Sandler. The question, please, Matthew.

Okay, thanks so much. We'd love to talk about this gross margin update, the mid-70s. I guess, Vaseem, what is it that you're seeing or that you are expecting now that gives you the confidence to raise it? I mean, something maybe around 400 to 500 basis points from what we were expecting before. And is the timeframe the same? versus the 70% you expected to get to, or is it just a little further out? And then I have a follow-up.

Yes, so just on gross margins, Matt, thanks for the question. We have now expanded gross margins 11 quarters in a row, with margin increasing over 10 points year-over-year in this quarter. We continue to benefit from high-revenue profit based on improvements on our in-network mix and also all of the CIP programs are delivering results. As we have said previously, You should see steady and consistent sequential increases in gross margin going forward. We have good line of sight to achieving gross margins of the mid-70% that we talked about over the next few years, driven by the attractive unit economics inherent in the business model that we have talked about in the past. But this is up from our prior view of 70%, and the confidence really comes from three things. One is the reduction in cost per fit driven by the progress of the programs. The volume-based reductions that we're seeing from our suppliers, improvements in revenue per fit, mostly driven by this in-network mix continuing to move higher. And we feel really confident that the unit economics plus the volume growth that we expect over the years will help us get to that mid-70% gross margin.

Okay, appreciate that. I guess to follow up on Larry's question on the guide, if I look at, you know, the cadence here, expecting more in the back half of the year in terms of the acceleration, would lead you to some pretty big numbers in Q3 and Q4, especially Q4 sequentially versus what you've done, you know, what you did in fiscal 26. So what are you seeing from a productivity perspective, splitting these territories and seeing improved You know, productivity from those regions, et cetera, that gives you the confidence that you're going to be able to get to these levels, you know, throughout the course of the year. Thanks so much.

Yeah, thanks, Matt. First of all, I appreciate you pointing out that that's a big quarter of that last one of the year. We agree. But, you know, I think what we're seeing, we gave a couple of hints in the prepared commentary. What we're seeing is we're having success as we split some of the larger territories and we double down into those territories. So we're seeing the rep productivity opportunity be significant as we further penetrate some of these accounts. And then the national leverage that we will get from the cohort of reps that we hired late in FY26 and here in the Early stages of FY27 will start to see productivity in the back half of the year. So it's a combination of those things that really gives us the confidence. Plus, a lot of the benefit we will see from some of our ongoing marketing programs that support the commercial team, and we expect the combination of all those things to lead to that kind of growth.

Understood. Thank you.

Thank you. Our next question comes from the line of Michael Pollard of Wolf Research. Please go ahead, Michael.

Hey, good afternoon. Thank you. I know the disclosure is changing, but I'm going to take a crack at it anyways. In the quarter, you beat the street by 7% on revenue. I'm wondering if you'd help us frame The portion of that beat from volume versus the portion of that beat from revenue per fit relative to what you think the consensus model was. I'm just working to keep the model build as high quality as it can be as we enter this new era. Thank you.

Yeah, so great question. We're obviously not commenting on the different elements of our previously communicated conversion rate, Mike, but We can tell you that we saw continued improvement in all of the KPIs that drive the REVVY model, which is the fill rate, the bill rate, and obviously the in-period collections. So we feel really good about where we are, and as we have said, the best way to kind of think about the growth relative to prescription is to look at the historicals In the past, the prescription performance has lagged the revenue number by a couple of points. And that relationship will hold for this year as it has in the past. And we feel really confident about looking at the data that way. And we will be providing you those details at the end of the year as we have promised. So overall, like I said, the KPIs are tracking all in the right direction. And we really feel great about the rest of the year as we head into the second quarter.

I'll pull the seam, thank you. For the follow-up, Brian, I'm curious for more color on one of your mentions. So you mentioned a large commercial payer is now covering the non-ischemic population and that's the first time that's happened. Clinical evidence cited as the reason, I think we can understand that. My question is how many commercial payers don't cover the non-ischemic population? Is this the last mover or is this a first mover or one in the middle? I'd be curious where we are on that side.

Yeah, that's a good question, Mike. Among the large payers, I would say this was the outlier. Most of the large payers already covered that patient population. This one had been one that had sort of held out on that for a long time and just recently came back with a new coverage decision. There are other regional and smaller payers that have took similar positions to that large payer. And so we're optimistic that we'll also see some movement with some of them. But it's a good signal. It's a good indicator that some of the evidence around the actual risk for some of these patients is starting to make a difference as we've been able to communicate it and I think that you're seeing that in the 14% market growth and you're seeing that in payer coverage decisions like this.

Thank you.

Thank you. Our next question comes from the line of Marie Tybalt of BTIG. Please go ahead, Marie.

Yes, thank you. Good evening. Thanks for taking the questions. I wanted to sort of understand a little bit more about the accelerated investment that you've called out in some of these key R&D programs. Should we expect R&D spend to be a little bit higher than we'd previously been thinking about for the rest of the year? How would you have us think about the cadence of some of those investments? And then as part of that, you mentioned with the AI efforts, you're going to hopefully curb Thank you very much, Brad. I'll take the R&D question and Vaseem, you can grab the AR question. So on the R&D question, we do believe that those

We believe that the RMD expense line will go back down. In my experience, when you have a multiyear RMD program that is coming close to the end of its schedule and you have an opportunity to apply financial resources to accelerate and protect that schedule, that's a bet I will make every day of the week, and that's what we did. and we feel good about that investment. We think that's going to net the results that we are looking for. But we do see that the R&D line, when it comes to the spend, will come back down in the four quarters.

And I think, Brian, just to kind of add to that, Brady, this overall commentary on kind of OPEX, we did see the OPEX came in slightly higher at $55 million than our previously communicated number. And that was really driven by, You know, the BioMeet milestone payments, but I think more importantly, you'll see, you know, overall R&D spend was up about 70%, which is significantly higher than what it has been historically. And that's really to kind of wrap up or almost finalize the investment in the R&D program. So, and that's why we're ready to kind of talk about some of the details here in the next 90 days. We expect the GAMP OPEX for the year to be at $220 million in 2027. which reflects continued investment on the commercial side. And then I think to Brian's point, the already standard turning back to historical levels, which is somewhere in the 5% to 7% range in the second half of the year. But that 220 would still mean an OPEX growth of 20% in fiscal year 27 versus a guidance of 48%. So we will continue to drive significant operating leverage on OPEX overall But I think a lot of that operating leverage in outer years, not this year, is predicated on some of these AI programs. But we are making investments this year that will help us bend the cost curve for revenue cycle management and improving rep productivity and things like that that Brian talked about in the prepared remarks.

All right. That's very helpful. Thank you. And then my follow-up, just a curiosity really. I recall last quarter you flagged that, you know, a meaningful I think historically the relationship between the revenue growth and prescription has been that prescriptions has lagged by a couple points and I think that will continue for this year. Thank you.

Thank you. Our next question comes from the line of Rick Wise of Stifel. Your line is open, Rick.

Thank you very much.

Good afternoon, everybody. Maybe, Vaseem, you could help us think through thoughtfully the quarterly cadence as we proceed through the year.

You've been very clear about the second half being higher, larger, bigger than the first half. But that was the pattern last year as well, of course. But last year as well, the dollars each quarter had a nice step up walking through to make that stronger half as well. Back to Marie's excellent question, was there anything unusually strong or one-time in nature in the first quarter it might make us think anything other than we'll see whatever it is a solid you know million or two million sequential step up quarterly into the second quarter and then sort of more of the same as you get into the second half and that as you note the rep productivity accelerates etc.

So right so yeah so again right Great question, great try. I think I'm going to say it one more time, slightly differently. I think if you think about last year, this is Q1, we were just coming off of the IDO, and if you remember at that time, we had just started to ramp up the hiring of the sales team, and that was the contract last year, which was that we know there's a ramp, we know what that ramp looks like, and as we have said in the past and we'll say today, Our REG productivity continues to ramp to that model that we have discussed with you guys in the past. So yes, the 60% revenue growth in Q1 is a favorable comp off of that 19 and change number from Q1 last year. But then at the same time, when you look at the guidance that we are providing here for the remainder of the year, the first half versus the second half is consistent there's no difference and that's also predicated again this year based on the significant hiring that we did in the last six months and those reps ramp up and put points on the board so there's nothing different this year than last year. Okay thank you.

As you can tell we're all obsessed. Just as a follow-up question I wanted to I'm not quite sure how to ask that question but I wanted to follow up Brian and your your extended commentary and not the same as every quarter commentary on AI and automation initiatives bending I think you said the operating margin growth curve. You broke up a little bit.

I couldn't quite get your exact language but given that focus and your intensity about this and all the

points you made, different points. Is there one or two of these in particular that are going to be meaningful? And when do we see the impact? Is this happening right now? Are we going to see it more in fiscal 28?

Just help us better understand the implications of all this work you're doing. Thank you.

Yeah, thank you, Rick. Appreciate that question. You know, I would say a couple things. First of all, when we look at the cost per dollar of revenue that comes from the volume-based G&A functions, that's where we see that curve starting to occur on the expense side. We've started to see that Gradually here in FY27, we expect that to accelerate in FY28 and 29 as we implement more of the technologies. We think there's a really nice opportunity in this business when you've got this many transactions and this volume impact of additional market share, then if you don't implement the automation, then you are You are committing yourself to human volume-based G&A investment. And so what we're trying to do is get ahead of that with the investments in the technology stack that I talked about and the AI and automation. And we've started to see a little bit of that benefit now, and we'll see that curve accelerate as we move into next year and the year beyond.

Thank you, Brian.

Thank you. Our next question comes from the line of Travis Steed of B of A. Your line is open, Travis.

Hi, this is Stephanie Algazian for Travis. Thanks for taking the question and congrats on a good quarter. With the guide update, I was curious if there's any updates to how you're thinking about market expansion and market share. You noted market growth of around 14% this past quarter. Any expectations for where that can go this year? And then on market share, you had expected incremental share gains this year versus the four points you gained last year. So any updates in terms of market share as well?

Yeah, thanks for the question, Stephanie. I think in terms of market growth, you know, the market is definitely accelerating and seeing, you know, that Market growth has essentially doubled since the IPO, and so we don't have any reason to believe that it's going to decelerate at this point, especially when we see that our competitor is spending a significant amount of energy on pushing the market growth in the category, and obviously we are doing that as well. So we expect that to continue to grow. How fast that grows or not is difficult to call at this point. We think in this most recent quarter we're somewhere around 15% market share in the U.S. market. And certainly when we're growing at 60% and our competitors are growing at a fraction of that, then that means that we're going to continue to capture share. And I think You know, in our long-range planning, we have fairly modest assumptions around market share and where that goes, and we're ahead of schedule when it comes to that. We expect to continue to see, you know, really nice gains as we field a larger team and we field some of this additional capability and innovation that we talked about.

Thank you. That's helpful. And then you talked about new reps ramping faster than prior cohorts. I'm curious what you're seeing now versus before. And is there a way to frame how much revenue growth is driven by account expansion versus deeper penetration into existing accounts?

Well, the new cohorts ramping more rapidly I think has to do with some of the investments we've made in both our recruiting capabilities and our training capabilities. We really made a big investment in how rigorous our training is for our new territory managers as they come into the company. And we're seeing the benefits of that. I think we've got a mix between We're going deeper in some of the accounts and splitting some of the territories, as I mentioned. But we're also expanding into new territories where we haven't had a presence at all. And some of the exciting growth that we're seeing is definitely coming from those expansion territories. So it'll be a mix. I don't know the exact ratio right now, but I think we'll continue to see a mix between going deeper in certain territories versus expanding into brand new territories.

Thank you. Our next question comes from the line of Robbie Marcus of JP Morgan. Please go ahead, Robbie.

Hi, thanks for the question. This is Alan on for Robbie. Just one quick one.

You previously talked to gross margin expansion of around 700 basis points. You know, sounded very bullish on gross margin progression and outperforming expectations so far in the first quarter. So just curious if you have an update on that, similar to how you updated operating expense expectations. Thank you.

Yeah, so, yes, we did comment on the 70% now kind of heading north to kind of the mid-70s. We do expect that, you know, based on the current gross margin guidance, that 700-point expansion for next year is pretty solid. But as you think about the gross margin number for fiscal year 2029, we expect for the year to deliver 70% gross margin. And that would basically give you a pretty clear line of sight that the second half of that year is going to be gross margin that's going to be north of 70%. So, again, we're not talking about mid-70s in five years. We're talking about mid-70s in the next two to three years. And we're very optimistic and have a lot of confidence in our ability to get there.

Once again, to ask a question, please press star 1-1 at this time. Our next question comes from the line of Suraj Kalia of Oppenheimer & Company. Your line is open, Suraj.

Good afternoon, Brian, Vaseem. Congrats on a nice quarter. Gentlemen, two questions, one for Brian and one for Vaseem. Vaseem, 14% nominal growth Can you characterize it by unit growth and where you all stood in terms of share? And Brian, my second question, I'll ask that up front. One of your comments caught my attention about AI, and I'm just paraphrasing here, your endeavor for AI to help improve fittings per rep. I guess I'm curious, you know, what kind of data You're going to have your AI models to improve this metric because it could have pretty interesting implications for improving on patient acquisition costs over time. Gentlemen, thank you for taking my questions.

Sorry, let me take the morning piece first. As I said in my previous commentary to the questions, since we're not commenting on Prescriptions and Fittings, and we committed to providing that on an annual basis. I'll just kind of close and provide more clarity. The conversion rate, as we used to talk about, was up, and all of the elements that drive that conversion rate were all trading better than expected. So the 60% growth that we delivered this quarter was a direct consequence of that. and again as we've said when we give you that annual number at the end of this year on prescriptions and fittings like we did last year you will see that the relationship between revenue and the prescriptions will hold that prescriptions being a couple points slower than the top line and that's predicated on us continuing to make improvements in our MD cycle management capabilities and the ability to fit those patients in

Yeah, thanks, Suraj. On the revenue of the fittings for sales rep, that's really a measure of sales rep productivity, so it's really about using some of those AI tools to free up time to make the rep give them more data to be able to Decide how they spend their day, where they spend their day, where the insights are that allow them to better manage their territories. And ultimately, as we make them more efficient, then that means they can spend more time penetrating the accounts that they get into. And that then leads to the higher fittings per sales route. And yeah, you're spot on when you say that that's That's a pretty meaningful metric. I think it's very clear to us that when we think about the path to profitability, that path to profitability, that road runs right through productivity. And that's why we're investing in some of those tools, why we're investing in all the training capability and recruiting capability and all those things with regards to our commercial team.

So appreciate that question.

Thank you. I would now like to turn the conference back to Brian Webster for closing remarks. Sir?

Thank you. And thank you all for your great questions and for attending the call. We're obviously excited by the start to the year. We're certainly bullish on our story. And, you know, when it comes down to it, when you have a product that is clearly superior You have a category where there is an unmet need of a significant number of patients. You have the ability to expand your commercial team to cover the market. You have clinical evidence that is compelling. And you add into those new innovation. That all leads to market growth and it leads to rapid We're very proud of the execution that the team has had over the prior quarters, including this Q1 that we're reporting on now. We're just getting the year started. It's a new year. It's a new business plan. We have new priorities this year, and as we fold those in and We're excited about executing the plan for FY27. So thank you very much and we'll look forward to updating you again in a few months.

This concludes today's conference call. Thank you for participating. You may now disconnect.